AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AbelZeta will receive up to $630m from AstraZeneca, including upfront payments and milestone fees for GPC3. Credit: grandbrothers / Shutterstock.com.



  • AstraZeneca AbelZeta therapy